You are here

Chemotherapeutic Selection of iPSCs for PD

Non-genetic methodologies to reduce undesirable proliferation would represent a valuable tool when generating dopamine neurons from human induced pluripotent stem cells (iPSCs). Researchers led by Jeffrey H. Kordower (Rush University, Chicago, Illinois, USA) modified an established method for the differentiation of human iPSCs into midbrain dopamine neurons using mitomycin‐C, an FDA‐approved chemotherapeutic. Reporting in STEM CELLS Translational Medicine, Hiller et al. report that while cells manufactured using mitomycin‐C had low proliferation, they displayed a level of survival and function comparable to dopamine neurons derived using genetic drug selection following their transplantation into a rat model of Parkinson's disease.